In adult patients with CKD associated with T2D

Mineralocorticoid receptor (MR) overactivation is an important factor to consider when evaluating the risk of CV events and CKD progression1

Graphic outlining the mechanism of disease. MR overactivation is thought to contribute to inflammation and fibrosis in patients with CKD associated with T2D.
Red warning bubble icon

Inflammation and fibrosis can contribute to permanent structural damage in your patients' kidneys and heart3-9

KERENDIA is a first-in-class nonsteroidal MR antagonist (ns-MRA) that blocks MR overactivation1


  • Blocks MR overactivation in tissues such as kidneys, heart, and blood vessels
  • Blocks MR-mediated sodium reabsorption
Graphic image depicting the mechanism of action of KERENDIA® (finerenone)

Has no relevant affinity for androgen, progesterone, estrogen, and glucocorticoid receptors

CKD=chronic kidney disease; CV=cardiovascular; MOA=mechanism of action; MOD=mechanism of disease; MR=mineralocorticoid receptor; T2D=type 2 diabetes.


KERENDIA is indicated to reduce the
risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)



  • Concomitant use with strong CYP3A4 inhibitors
  • Patients with adrenal insufficiency


  • Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L


    Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium


  • From the pooled data of 2 placebo-controlled studies, the adverse reactions reported in ≥1% of patients on KERENDIA and more frequently than placebo were hyperkalemia (14% vs 6.9%), hypotension (4.6% vs 3.9%), and hyponatremia (1.3% vs 0.7%)


  • Strong CYP3A4 Inhibitors: Concomitant use of KERENDIA with strong CYP3A4 inhibitors is contraindicated. Avoid concomitant intake of grapefruit or grapefruit juice
  • Moderate and Weak CYP3A4 Inhibitors: Monitor serum potassium during drug initiation or dosage adjustment of either KERENDIA or the moderate or weak CYP3A4 inhibitor and adjust KERENDIA dosage as appropriate
  • Strong and Moderate CYP3A4 Inducers: Avoid concomitant use of KERENDIA with strong or moderate CYP3A4 inducers


  • Lactation: Avoid breastfeeding during treatment with KERENDIA and for 1 day after treatment
  • Hepatic Impairment: Avoid use of KERENDIA in patients with severe hepatic impairment (Child Pugh C) and consider additional serum potassium monitoring with moderate hepatic impairment (Child Pugh B)

Please read the Prescribing Information for KERENDIA.

References: 1. KERENDIA (finerenone) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals, Inc.; September 2022. 2. Jaisser F, et al. Pharmacol Rev. 2016;68(1):49-75. doi:10.1124/pr.115.011106. 3. Bauersachs J, et al. Hypertension. 2015;65(2):257-263. doi:10.1161/HYPERTENSIONAHA.114.04488. 4. Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. doi:10.2215/CJN.11491116. 5. Thomas C, et al. Nat Rev. 2015; doi:10.1038/nrdp.2015.18. 6. Black LM, et al. J Histochem Cytochem. 2019;67(9):663-681. doi:10.1369/0022155419852932. 7. Tesch GH, et al. Front Pharmacol. 2017;8:313. doi:10.3389/fphar.2017.00313. 8. Panizo S, et al. Int J Mol Sci. 2021;22(1):408. doi:10.3390/ijms22010408. 9. Charlton A, et al. Biology (Basel). 2020;10(1):18. doi:10.3390/biology10010018.